Cited by 522Cancer Immunotherapy and BiomarkersCancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia

Open access

Scharping, Nicole E., Menk, Ashley V., Whetstone, Ryan D., Zeng, Xue, Delgoffe, Greg M.·2017·Cancer Immunology Research

DOI 10.1158/2326-6066.cir-16-0103PMC PMC5340074

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Blockade of the coinhibitory checkpoint molecule PD-1 has emerged as an effective treatment for many cancers, resulting in remarkable responses. However, despite successes in the clinic, most patients do not respond to PD-1 blockade. Metabolic dysregulation is a common phenotype in cancer, but both patients and tumors are metabolically heterogeneous. We hypothesized that the deregulated oxidative energetics of tumor cells present a metabolic barrier to antitumor immunity through the generation of a hypoxic microenvironment and that normalization of tumor hypoxia might improve response to immunotherapy. We show that the murine tumor lines B16 and MC38 differed in their ability to consume oxygen and produce hypoxic environments, which correlated with their sensitivity to checkpoint blockade. Metformin, a broadly prescribed type II diabetes treatment, inhibited oxygen consumption in tumor cells in vitro and in vivo, resulting in reduced intratumoral hypoxia. Although metformin monotherapy had little therapeutic benefit in highly aggressive tumors, combination of metformin with PD-1 blockade resulted in improved intratumoral T-cell function and tumor clearance. Our data suggest tumor hypoxia acts as a barrier to immunotherapy and that remodeling the hypoxic tumor microenvironment has potential to convert patients resistant to immunotherapy into those that receive clinical benefit. Cancer Immunol Res; 5(1); 9–16. ©2016 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-16-0103

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 7×
“org Cancer Immunol Res; 5(1) January 2017 11”
BackgroundInfluential
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331 · cited 2×
“can be metabolically plastic, and are primed to utilize glucose in oxygen-poor conditions, glucose, too, can be limiting in the tumor microenvironment (15,16).”
Background
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“It is established that patients taking metformin for type II diabetes have a decreased risk of cancer (17, 18) and that much of the antitumor metformin effect can be attributed to T cells (19).”
Background
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462 · cited 2×
“However, in the tumor microenvironment, as glucose is limiting, only cells able to effectively compete for glucose would experience an enhanced response (15, 16).”
Background
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
Self-citation
Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism
Peng, M., Yin, N., Chhangawala, S., Xu, K., Leslie, C. S., & Li, M. O. (2016) · Science · doi:10.1126/science.aaf6284 · Cited by 787 · cited 1×
“to effector function epigenetically and post-transcriptionally (26-28).”
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 708 · cited 1×
“We have previously shown that T cells in the tumor microenvironment are at a metabolic disadvantage and repress oxidative metabolism (13).”
BackgroundSelf-citation

Show all 30 references

Sorted by citations

Items 401–500 of 522

Targeting Tumor Hypoxia
Skwarski, M., Bowler, E., Wilson, J. D., Higgins, G. S., & Hammond, E. M. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_11 · Cited by 7
Statins attenuate PD-L1 sorting to small extracellular vesicles dependent on ubiquitin-like 3 modification
Ageta, H., Shimada, Y., Nagaoka, T., Takenaka, K., Yoshioka, Y., Konno, K., Amemiya, R., Nagase, K., Hitachi, K., Onouchi, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-27789-x · Cited by 5
Metformin promotes anti-tumor immunity in STK11 mutant NSCLC through AXIN1-dependent upregulation of multiple nucleotide metabolites
WANG, Z., Li, K., Lu, C., Feng, M., Lin, C., Yin, G., Luo, D., Liu, W., Jin, K., Dou, Y., et al. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.052664 · Cited by 5
“Furthermore, it has been reported that metformin can potentiate anti-tumor immunity by inducing the reduction of tumor hypoxia [14], and via activation of the nuclear factor E2-related factor 2 (Nrf2)/mammalian target of rapamycin complex 1 (mTORC1)/p62 axis in tumor-in ﬁ ltrating CD8 T cells [15].”
Background
Metformin as an immunomodulatory agent in enhancing head and neck squamous cell carcinoma therapies
Li, W., Liu, N., Chen, M., Liu, D., & Liu, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189262 · Cited by 5
Development and Validation of a Hypoxia-related Prognostic Model for Ovarian Cancer
Xie, L., Pan, M., Zhang, Z., Jiang, X., Chen, Y., Liu, G., Chen, Y., Zeng, Y., Guan, J., Lu, R., et al. (2022) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892817666220623154831 · Cited by 5
Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence
Mirabile, A., Rivoltini, L., Daveri, E., Vernieri, C., Mele, R., Porcu, L., Lazzari, C., Bulotta, A., Viganò, M. G., Cascinu, S., et al. (2020) · Cancers · doi:10.3390/cancers12051153 · Cited by 5
“For instance, anti-PD-1 and anti-CTLA-4 monoclonal antibodies can reactivate glycolysis and other metabolic pathways in exhausted T cells, thus promoting their activation and antitumor functions [22,158,159].”
BackgroundInfluential
Oral Metformin and Polymetformin Reprogram Immunosuppressive Microenvironment and Boost Immune Checkpoint Inhibitor Therapy in Colorectal Cancer
Xiong, Y., Song, W., Shen, L., Wang, Y., Zhang, J., Hu, M., Liu, Y., Li, J., Musetti, S., Liu, R., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000168 · Cited by 5
Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non–small cell lung cancer
Elkin, P. L., Mullin, S., Tetewsky, S. J., Resendez, S. D., McCray, W., Barbi, J. J., & Yendamuri, S. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.02.046 · Cited by 5
Imaging Memory T-Cells Stratifies Response to Adjuvant Metformin Combined with αPD-1 Therapy
Goggi, J., Hartimath, S. V., Khanapur, S., Ramasamy, B., Feng, C. Z., Cheng, P. K. C., Chin, H. X., Hwang, Y. Y., & Robins, E. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112892 · Cited by 5
“When used as an adjunct, metformin’s ability to modulate the tumour microenvironment can significantly improve the magnitude and durability of tumour-infiltrating T-cells in response to the PD-1 blockade [9]; however, metformin has little effect on the quantity or type of tumour infiltrating immune cells when delivere…”
Background
Are metformin-based combination approaches beneficial for non-small cell lung cancer: evidence from experimental and clinical studies
Thyagarajan‐Sahu, A., Gajjar, V., & Sahu, R. P. (2025) · Military Medical Research · doi:10.1186/s40779-025-00649-5 · Cited by 6
Drug Repurposing in Oncology: A Strategic Pathway to Unlocking New Therapeutic Potential
Shaik, R., Laddika, S. G., Unnisa, M., Hamza, A., Begum, S., & Sarwar, S. F. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00895-8 · Cited by 4
“Furthermore, Scharping et al. discovered that metformin increased T cell activity in the nutrient-depleted tumor microenvironment (TME), increasing the efficiency of adoptive T cell therapy [ 56].”
Metformin as an anti-cancer agent against bladder cancer acts via PD-L1 downregulation in an orthotopic mouse model
Yeh, C.-C., Tsai, P.-C., Song, Y.-D., Low, Y.-S., Hsu, C., Yang, S.-J., Chen, Y.-Y., & Dou, H.-Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14930-2 · Cited by 4
“Several preclinical studies have shown that combining metformin with immune checkpoint blockade or targeted therapies results in synergistic antitumor effects [49, 50].”
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
Rimini, M., Montes, M., Amadeo, E., Vitiello, F., Kudo, M., Tada, T., Suda, G., Shimose, S., Lonardi, S., Finkelmeier, F., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-70928-z · Cited by 4
Let there be oxygen and T cells
Walker, P. R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci124305 · Cited by 4
“Hypoxia reduction can also be achieved by inhibiting oxygen consumption of tumors using the metabolic drug metformin, suggested to impede cancer progression and to promote responsiveness to immunotherapy (9).”
Mapping the spatial architecture of glioblastoma from core to edge delineates niche-specific tumor cell states and intercellular interactionsPreprint
Khan, S. M., Wang, A. Z., Desai, R. R., Kim, G. D., McCornack, C. R., Sun, R., Dahiya, S. M., Foltz, J. A., Sherpa, N. D., Xu, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647096 · Cited by 6
Multi omics analysis of mitophagy subtypes and integration of machine learning for predicting immunotherapy responses in head and neck squamous cell carcinoma
Liu, J., Li, H., Dong, Q., Liu, C., Li, Z., & Liang, Z. (2024) · Aging · doi:10.18632/aging.205964 · Cited by 3
Spatial genomics reveals cholesterol metabolism as a key factor in colorectal cancer immunotherapy resistance
Kavran, A. J., Bai, Y., Rabe, B. A., Kreshock, A., Fisher, A., Cheng, Y., Lewin, A. C., Dai, C., Meyer, M. J., Mavrakis, K. J., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1549237 · Cited by 3
Immunological Drug–Drug Interactions in Immune Checkpoint Inhibitor Therapy: Mechanisms, Clinical Evidence, and Artificial Intelligence
Yiu, C. H., Winardi, K., & Lu, C. Y. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01789-0 · Cited by 3
“Metformin has attracted considerable interest due to pre-clinical data indicating potential enhancement of PD-1 blockade through reduced tumour hypoxia and activation of the AMPK pathway [62].”
Tumor–immune metabolic tug-of-war: from immune escape to targeting metabolic rewiring in cancer therapy
Foglia, B., Nurcis, J., Signorini, M., & Cannito, S. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1823145 · Cited by 3
“Importantly for immunotherapy design, metformin is also linked to functional “re-oxygenation” of tumors, where metformin-mediated reduction of tumor hypoxia potentiated responsiveness to PD-1 blockade (Scharping et al., 2017).”
Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists
Temperley, H. C., & Kelly, M. E. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00062 · Cited by 3
“35 Patients with T2D have been shown to have worse cancer outcomes than those without T2D.”
Overcoming T-cell exhaustion in glioblastoma
Wang, X., Wang, X., & Li, J. (2022) · Glioma · doi:10.4103/glioma.glioma_16_22 · Cited by 3
Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancer
Coleman, M., Mascialino, S. J., Panjwani, A., Edwards, E., Sukhatme, V. V., Gavegnano, C., & Sukhatme, V. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1281744 · Cited by 4
“The impact of metformin and anti-PD-1 immunotherapy on colon cancer and melanoma in vitro and in vivo mouse models has been investigated (37).”
Background
Optimizing CAR-T cell function in solid tumor microenvironment: insights from culture media additives
Chen, W., Xu, L., Guo, Z., & Zhou, M. (2024) · Current Research in Translational Medicine · doi:10.1016/j.retram.2024.103491 · Cited by 3
Biomimetic photosynthesis nanoreactors based thylakoid synergy with metformin for reversing tumor immunosuppressive microenvironment therapy
Zhong, P., Zhao, Y., Cui, H., Cheng, G., Xia, L., Tian, Z., Liu, W., Wu, J., Yu, J., Peng, X., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.163368 · Cited by 3
Immune regeneration: implications for cancer immunotherapy and beyond
Reiner, S. L. (2025) · Journal of Clinical Investigation · doi:10.1172/jci192731 · Cited by 3
The Role of Intra-Tumor Hypoxia in Cancer Cells Immune Escape Mechanism
Farhangnia, P., Delbandi, A., Aghamohamadi, N., Safdarian, A. R., & Akbarpour, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_61-1 · Cited by 3
Metabolic Reprogramming of Anti-cancer T Cells: Targeting AMPK and PPAR to Optimize Cancer Immunotherapy
Jalil, A. T., Al-Kazzaz, H. H., Hassan, F., Mohammed, S. H., Merza, M. S., Aslandook, T., Elewadi, A., Fadhil, A. A., & Alsalamy, A. (2024) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-023-01166-9 · Cited by 3
“Another by-product produced by tumor cells that can suppress the immune system is adenosine, which is generated by the breakdown of ATP in tumor cells [37].”
Clinical Effect of Treatment with Metformin for Type 2 Diabetes on Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: A Retrospective Study
Wang, Y., Sun, Y., Hu, J., & Ma, H. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s495449 · Cited by 3
“17 Eikawa et al reported that the direct effect of metformin on CD8 (+) T cells was crucial for preventing inevitable functional failure in the tumor microenvironment.”
Drugs repurposed to potentiate immunotherapy for cancer treatment
To, K. K. W., & Cho, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819668-7.00012-9 · Cited by 3
Citius, Altius, Fortius: Performance in a Bottle for CAR T-Cells
Ayari, A., & O’Connor, R. S. (2020) · Journal of Clinical Haematology · doi:10.33696/haematology.1.015 · Cited by 3
“Restoring their oxidative state enhances the efficacy of anti-PD-1 immune checkpoint blockade [5] Our findings suggest that carnosine confers a superior oxidative state to cultured T cells; an effect that often underlies improved mitochondrial function.”
Background
Stratified analysis identifies HIF-2 α as a therapeutic target for highly immune-infiltrated melanomasPreprint
Huang, A. Y., Burke, K. P., Porter, R. M., Meiger, L., Fatouros, P. R., Yang, J., Robitschek, E. J., Vokes, N. I., Ricker, C. A., Rosado, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.29.620300 · Cited by 3
“…cell types in more hypoxic samples, we observed upregulation of hypoxia response and EMT genes, and downregulation of oxidative phosphorylation (consistent with a progressive loss of mitochondria and oxidative metabolism in a hypoxic TME [37]), interferon gamma response, adhesion, and DNA repair.”
Melanoma Brain Metastasis
Hasanov, M., Açıkgöz, Y., & Davies, M. A. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.008 · Cited by 3
A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 Study
Ciccarese, C., Arduini, D., Primi, F., Sparagna, I., Strusi, A., Bisogno, I., Occhipinti, D., Pedone, R. R., Schinzari, G., Sighinolfi, M. C., et al. (2025) · Tumori Journal · doi:10.1177/03008916251384162 · Cited by 2
Real-World Impact of Metformin on Outcomes in Patients with Deficient DNA Mismatch Repair and Microsatellite Instability (dMMR/MSI) Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Gupta, G., Sadeghipour, N., Bicer, F., Elliott, A., Hinton, A. C., Lou, E., Vanderwalde, A. M., Özlük, A. A., Khushman, M. M., Malla, M., et al. (2025) · Cancers · doi:10.3390/cancers17243944 · Cited by 2
“Preclinical studies have reported observations that metformin modulates the TME, in part by decreasing PD-L1 expression [22–24], enhancing oxygen consumption by CD8+ TILs [25,26], and by promoting T cell function [27,28].”
Metabolism of tumor infiltrating T cells
Ertl, H. C. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1711328 · Cited by 3
Mitochondrial transfer-driven immune evasion in the tumor microenvironment
Zhu, L., & Togashi, Y. (2026) · International Immunology · doi:10.1093/intimm/dxag027 · Cited by 3
“Metformin improved antitumor immunity and potentiated PD-1 blockade in preclinical work through reduction of tumor hypoxia (71).”
Mitochondrial transfer in the tumor microenvironment: a dynamic determinant of cancer plasticity, immune dysfunction, and therapeutic opportunity
Xu, Z., Zhou, Q., & Miao, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1871148 · Cited by 2
“Metformin has often been invoked in this regard (118, 119), but the negative phase 2 trial combining metformin with PD-1 blockade is instructive (120): broad metabolic interventions may fail without biomarker-de ﬁ ned patient selection.”
The interaction between end-metabolites and immune escape
Zhu, T., & Wang, G. (2022) · Oncology and Translational Medicine · doi:10.1007/s10330-022-0573-3 · Cited by 3
Antitumor and immunomodulatory effects of oxygen therapy
Seledtsov, V. I., Б., Д. А., & Seledtsova, G. V. (2023) · Medical Immunology (Russia) · doi:10.15789/1563-0625-aai-2562 · Cited by 2
Potentiation of immune checkpoint blockade with an ITPP radiosensitizer studied with oxygen saturation measurements from photoacoustic imaging
Tran, R. L., Liang, X., de la Cerda, J., Schuler, F. W., & Pagel, M. D. (2025) · Scientific Reports · doi:10.1038/s41598-025-05930-0 · Cited by 2
“However, more studies with additional tumor models are needed to investigate whether the conversion of immunogenically “cold” tumors into “hot” tumors that have high T cell penetrance is a common feature of all cancer types 1,25 .”
Loss of ten-eleven translocation 2 (TET2) facilitates aggressive behaviour in cutaneous melanoma by inducing peroxisome proliferator-activated receptor-γ coactivator 1α expression and oxidative phosphorylation
Fischer, G. M., Fang, R., Xu, S., Karkempetzaki, A. I., Migayron, L., Draper, E. C., Wang, J., Schatton, T., Mandinova, A., Murphy, G. F., et al. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf378 · Cited by 2
A Novel Strategy to Fuel Cancer Immunotherapy: Targeting Glucose Metabolism to Remodel the Tumor Microenvironment
Liu, X., Zhao, Y., Wu, X., Liu, Z., & Liu, X. (2022) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr2ed.2.22.25 · Cited by 2
Opposing immune and genetic forces shape oncogenic programs in synovial sarcomaPreprint
Jerby‐Arnon, L., Neftel, C., Shore, M. E., McBride, M. J., Haas, B. J., Izar, B., Weissman, H. R., Volorio, A., Boulay, G., Cironi, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/724302 · Cited by 2
“16 oxidative phosphorylation to create a hypoxic niche and promote T cell dysfunction (41).”
Background
Programmed death-ligand 1 expression in human cancer three-dimensional cell culture modelsPreprint
Hudson, K., Cross, N. A., Jordan, N., & Leyland, R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.31.514495 · Cited by 2
Community awareness of hereditary blood diseases and the benefit of premarital screening program in Saudi Arabia
Elhefny, M., Alessa, A., Alzahrani, S., Almarhabi, Y. A., Almaedy, B., Alshaikhi, O. A., Alessa, H., Alghamdi, H., Alamri, A., & Alghamdi, T. H. (2022) · Medical Science · doi:10.54905/disssi/v26i128/ms424e2505 · Cited by 1
Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors
Kubo, T., Kato, H., Horiguchi, S., Kozuki, T., Asagi, A., Yoshida, M., Udono, H., Kiura, K., & Hotta, K. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02786-2 · Cited by 1
“Thus, a combination of metformin and PD-1 blockade promotes infiltration and activation of CD8 T cells within tumor, resulting in tumor clearance [13, 14].”
Effect of metformin on hypoxia-associated gene expression in oral cavity squamous cell carcinoma in non-diabetic patients - a prospective window of opportunity study
Mueller, S. A., Eliçin, O., Monney, B., Rau, T. T., Pra, A. D., Sachs, L., Ramos, I. C., Vassella, E., Dammann, F., Caparrotti, F., et al. (2025) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-025-09493-8 · Cited by 2
“…HNSCC. Notably, an increase of cytotoxic CD8 + T-lymphocytes, decrease of regulatory FOXP3 + lymphocytes and increased function of natural killer cells in tumors has been described, supporting the hypothesis that metformin may favorably alter the tumor microenvironment [9 , 10 , 11 , 12 , 39 , 49].”
Association Between Metformin Use and Mortality Among Individuals With Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
Sun, X., Heyward, J., Murray, J. C., Alexander, G. C., & Mehta, H. B. (2025) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000565 · Cited by 1
The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers
Potez, M., Souza, G. R., Spiess, P. E., Pilon‐Thomas, S., & Chahoud, J. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01088-6 · Cited by 1
The Role of Intra-tumor Hypoxia in Cancer Cells Immune Escape Mechanism
Farhangnia, P., Delbandi, A., Aghamohamadi, N., Safdarian, A. R., & Akbarpour, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00759-9_61 · Cited by 1
Metformin in gastrointestinal cancers and inflammatory bowel disease: Unraveling its mechanisms and therapeutic applications
Li, Y., Xingqi, G., Dong, X., Xia, T., Ma, S., & Liu, Z. (2026) · iScience · doi:10.1016/j.isci.2026.114877 · Cited by 1
“49 Broadfield et al. demonstrated that in mice on a high-fat diet, metformin reduced tumor growth by altering the gut microbiome.”
Pre-treatment endocrine–nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies
Huang, N., & Guan, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1753660 · Cited by 1
Metformin enhances response to chemotherapy combined with immunotherapy in a triple negative breast cancer in vivo model
Gámez‐Pozo, A., Vega-Clemente, L., Trilla‐Fuertes, L., López‐Camacho, E., Becerril-Gomez, F., Alonso-Martín, D., López‐Vacas, R., Lalanda-Delgado, P., Zamora, P. M., García‐Arranz, M., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119248 · Cited by 1
Mitochondria in sarcoma and carcinoma: Achilles’ heel or Hercules’ strength?
Ashrafi, M. R., Cayrefourcq, L., Rajabi, S., & Alix‐Panabières, C. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.03.004 · Cited by 1
Atovaquone-induced therapeutic rewiring of melanoma metabolism
Ponce, M. A. B., Heaton, A. R., Burkard, S. K., D’Amato, A., Boonpattrawong, N., Skala, M. C., Patankar, M. S., & Barroilhet, L. M. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.03.009 · Cited by 1
Clinically Validated Leptin Receptor as a Target for Liposomal Delivery of Metformin in Endometriosis Therapy
Xu, Y., Fang, Y., Wang, Y., Wu, R., Zhou, M., Lu, P., Wang, Y., He, Y. U. E. J. I., Zhang, J., Wei, Z., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c18417 · Cited by 1
The impact of comorbid type 2 diabetes on survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis focusing on lung cancer
Fan, L., Xu, W., Zhang, Q., Li, J., & Bai, W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1808976 · Cited by 1
Mitochondrial Stress Orchestrates Tumor Immune Evasion and Immunotherapy Resistance
Bılır, A., Yıldırım, B., & Karalök, M. H. (2026) · Cells · doi:10.3390/cells15100890 · Cited by 1
“Metformin, a complex I inhibitor, reduces tumor hypoxia and enhances PD-1 blockade efficacy in preclinical models, while also improving T cell survival under hypoxia [43,44].”
Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications
Tan, J., Wen, T., Liu, J. S., & Ru, X. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01828-0 · Cited by 1
“Metformin reduced tumor hypoxia and enhanced responses to PD-1 blockade in preclinical models [554].”
Mitochondrial Energy Metabolism in Cancer, Immunoregulation and Antitumour Response
Patrício, J. S., Mendes, C., & Gameiro, P. A. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_17 · Cited by 1
Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential
Xiang, M., Liu, S., Xiao, D., & Tao, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02810-5 · Cited by 1
“277 Additionally, mannose-modi ﬁ ed macro-phage-derived microparticles loaded with metformin (Met@Man-MPs) were developed to selectively target M2-like TAMs and repolarize them into an M1-like phenotype, which anti-PD-1 antibody therapy.”
Analyzing Melanoma Cell Oxygen Consumption and Extracellular Acidification Rates Using Seahorse Technology
Menk, A. V., & Delgoffe, G. M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1205-7_6 · Cited by 1
Self-citation
Anti-hypoxic Agents for Improving Head and Neck Cancer Therapy
Fraga, C. A. D. C., Souza, D. P. S. P., Lima, H. C. S., Farias, L. C., & Guimarães, A. L. S. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_69 · Cited by 1
Role of ROS in Combined Radiation Effect in Cancer Therapy
Gautam, A., & Goyal, L. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-5422-0_65 · Cited by 1
Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor
Zhou, Q., Liu, J., & Xie, S. (2024) · Medicine · doi:10.1097/md.0000000000038329 · Cited by 1
Metabolic Checkpoint of Immune Cells in Melanoma Brain Metastases
Egelston, C. A., & Margolin, K. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0249 · Cited by 1
“Additionally, other preclinical studies observed increased intratumoral T-cell numbers and tumor clearance with a combination of anti–PD-1 antibodies and metformin, a mitochondrial OXPHOS inhibitor (7).”
Metformin: A Small Molecule with Multi-Targets and Diverse Therapeutic Applications
Badria, A. F., Ali, A. R., Elbermawi, A., Amen, Y. M., & Badria, A. F. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.108884 · Cited by 1
Tumor hypoxia drives suppressor function in exhausted T cells limiting antitumor immunityPreprint
Delgoffe, G. M., Vignali, P., DePeaux, K., Watson, M. J., Lontos, K., McGaa, N., Scharping, N. E., & Menk, A. V. (2021) · Research Square · doi:10.21203/rs.3.rs-924657/v1 · Cited by 1
Self-citation
Overcoming tumor hypoxia
van der Wiel, A. M.-M. A. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230202aw · Cited by 1
Morphine and Metformin Impact Immunotherapy Benefit in Nsclc: Results of the Real-World Study Ifct-1502 Clinivo-SndsPreprint
Gobbini, É., Langlais, A., Missy, P., Chanoine, S., Besse, B., Souquet, P.-J., Barlési, F., Audigier-Valette, C., Métivier, A.-C., Monnet, I., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5194977 · Cited by 1
CAR T-Cell Therapy for CNS Malignancies
Sanber, K. S., Joseph, S. K., & Ahmed, N. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00012-3
Innovations in the treatment of non-small cell lung cancer
Wink (2019) · doi:10.26481/dis.20191204cw
Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom
Petrova, V., Arkhypov, I., Weber, R., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Kompass Dermatologie · doi:10.1159/000509449
NK cell-mediated immunotherapy: The exquisite role of PGC-1a in metabolic reprogramming
Gerbec, Z. J., & Malarkannan, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00006-0
Regulation of cellular metabolism in tumor infiltrating CD8+ T cells and its role in their dysfunction
Gemta, L. F. (2019) · Libra · doi:10.18130/v3-k04d-7r03
Reply to Letter to the Editor
Oh, M. S., & Villaflor, V. M. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.08.005
Role of ROS in Combined Radiation Effect in Cancer Therapy
Gautam, A., & Goyal, L. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_65-1
Optimizing the treatment of oesophageal cancer
Lien, V. D. V. (2020) · doi:10.26481/dis.20200506lv
Impacto da via de sinalização AMPK na modulação da resposta imune antitumoral por linfócitos T CD4>sup<+>/sup< e CD8>sup<+>/sup<
Feitosa, A. C. M. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2020.tde-18122019-110528
831 Targeting tumor oxidative metabolism to overcome hypoxia-induced immunotherapy resistance in prostate cancer
Jayaprakash, P., Curran, M. A., Morrow, B., Marszalek, J. R., Bhanu, K. R., Rice, M., Gay, J. P., Vellano, C. P., Cowen, B., & Welsch, D. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.0831
A novel hypoxia-related genes signature for prognosis and immunotherapeutic sensitivity in uterine carcinosarcoma patients
Jiaxin, Z. H. O. U., Yabing, Y. A. N. G., Jinghua, P. A. N., & Zhou, H. (2022) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.22.04799-4
A prognostic hypoxia gene signature is associated with a dampened tumour immune microenvironment in cervical cancer
Chouaı̈b, S., Khouzam, R., Venkatesh, G. H., & Rao, R. S. P. (2023) · Hamdan Medical Journal · doi:10.4103/hmj.hmj_60_22
Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
Paidi, S. K., Troncoso, J. R., Raj, P., Díaz, P. M., Ivers, J. D., Lee, D. E., Avaritt, N. L., Gies, A. J., Quick, C. M., Byrum, S. D., et al. (2023) · doi:10.1158/0008-5472.c.6513670.v1
Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
Paidi, S. K., Troncoso, J. R., Raj, P., Díaz, P. M., Ivers, J. D., Lee, D. E., Avaritt, N. L., Gies, A. J., Quick, C. M., Byrum, S. D., et al. (2023) · doi:10.1158/0008-5472.c.6513670
Data from A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Hegde, A. M., Jayaprakash, P., Couillault, C., Piha-Paul, S. A., Karp, D. D., Rodon, J. A., Pant, S., Fu, S., Dumbrava, E. E. I., Yap, T. A., et al. (2023) · doi:10.1158/1078-0432.c.6530310.v1
Data from Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti–PD-1 Immune Checkpoint Blockade
Triozzi, P. L., Stirling, E. R., Song, Q., Westwood, B. M., Kooshki, M., Forbes, M. E., Holbrook, B. C., Cook, K. L., Alexander‐Miller, M. A., Miller, L. D., et al. (2023) · doi:10.1158/1078-0432.c.6532389
Data from Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells
Drijvers, J. M., Gillis, J. E., Muijlwijk, T., Nguyen, T. H. P., Gaudiano, E. F., Harris, I. S., LaFleur, M. W., Ringel, A. E., Yao, C.-H., Kurmi, K., et al. (2023) · doi:10.1158/2326-6066.c.6550425.v1
Influence of Antibiotic Use on the Effectiveness and Safety of Immune Checkpoint Inhibitors
Minamishima, T., Hida, H., Miyazaki, M., Kon, S., Senzaki, K., Nagai, T., & Yamada, K. (2022) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.48.173
Identification and Verification of Disulfidptosis Patterns and Characterization of Tumor Microenvironment Infiltration via Multi-Omics Analysis in Lung adenocarcinomaPreprint
Liu, J., Li, H., Zhang, N., Dong, Q., Liu, C., Liang, X., Guo, S., & Liang, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-2945159/v1
The Causal Role of Metformin in Immune Cells Activation: A Mendelian Randomization StudyPreprint
Chen, P., Zheng, H., Ni, S., & Ouyang, L. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4631480
Additional file 2 of Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis
Chen, Y., Yu, Z., Lv, M., Cai, Z., Zou, Y., Lan, P., Wu, X., & Gao, F. (2021) · Figshare · doi:10.6084/m9.figshare.16909933
Targeting mitochondrial metabolism to improve the tumor microenvironment: A bibliometric study and brief review (1994-2024)Preprint
Zheng, H., Wang, G., Wu, J., Liu, M., & Cheng, H. (2024) · Research Square · doi:10.21203/rs.3.rs-4922171/v1
Variations in Myocardial FDG Uptake and Metformin Use: Implications for Survival during Immunotherapy
Torres, M. C., Fagundes, J. G. M., Botelho, L. F. B., Verçosa, A. F. A., & de Melo, M. D. T. (2025) · ARQUIVOS BRASILEIROS DE CARDIOLOGIA - IMAGEM CARDIOVASCULAR · doi:10.36660/abcimg.20240108i
Metformin in the prevention and treatment of colorectal cancer
Hromakova, I. А., Сорочан, П. П., Prokhach, N. E., Hromakova, I. S., & Olkhovskyi, D. V. (2025) · Український радіологічний та онкологічний журнал · doi:10.46879/ukroj.1.2025.82-99
“Literature review metabolic resources to perform effector functions, including tumor clearance [80].”
Antidiabetic agents as potential cytotoxic candidates for cancer therapy
Alnaser, R. I., Alassaf, F. A., & Abed, M. N. (2024) · Forum of Clinical Oncology · doi:10.2478/fco-2023-0041 · Cited by 1
Cellular Metabolism Controls Lymphocyte Activation and Differentiation
Powell, J. D., & Sun, I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00180-0
Metabolic programming and immune suppression
Wang, Y., & Ma, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00054-0
Harnessing Single-Cell RNA-Seq for Computational Drug Repurposing in Cancer Immunotherapy
Cheng, O., Tran, T. T., Chen, Y. A., & Tan, A. C. (2025) · Pharmaceuticals · doi:10.3390/ph18111769
“…metabolic modulators, hormone receptor inhibitors, immunomodulators, and anti-inflammatory agents, as well as microbial therapy—have been studied in preclinical studies, and these same agents, or others targeting similar pathways, are currently being evaluated in clinical trials [22–27] (Table 1).”
Additional file 1 of Novel hypoxia- and lactate metabolism-related molecular subtyping and prognostic signature for colorectal cancer
Huang, A., Sun, Z., Hong, H., Yang, Y., Chen, J., Gao, Z., & Gu, J. (2024) · Figshare · doi:10.6084/m9.figshare.26737023
Additional file 2 of Novel hypoxia- and lactate metabolism-related molecular subtyping and prognostic signature for colorectal cancer
Huang, A., Sun, Z., Hong, H., Yang, Y., Chen, J., Gao, Z., & Gu, J. (2024) · Figshare · doi:10.6084/m9.figshare.26737026

Authors: Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X., & Delgoffe, G. M.
Affiliations: University of Pittsburgh (US)
UPMC Hillman Cancer Center (US)
Corresponding author: Delgoffe, Greg M.
ORCID: Scharping, Nicole E.
Menk, Ashley V.
Zeng, Xue
Delgoffe, Greg M.
Venue: Cancer Immunology Research
Publisher: American Association for Cancer Research (AACR)
Published: 2017-01-01
Volume: 5
Issue: 1
Pages: 9-16
ISSN: 2326-6066 (ISSN-L)
2326-6074
DOI: 10.1158/2326-6066.cir-16-0103
PMC: PMC5340074
OpenAlex: W2560185130
Cited by: 520
References: 30
Citations by year: 2026: 34 · 2025: 53 · 2024: 49 · 2023: 72 · 2022: 85 · 2021: 79 · 2020: 69 · 2019: 38 · 2018: 30 · 2017: 11
FWCI: 14.18
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Immunology Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: UPCI (P30CA047904)
Sidney Kimmel Foundation for Cancer Research (SKF-015-039)
University of Pittsburgh Cancer Institute Skin Cancer (P50CA121973-08)
University of Pittsburgh Cancer Institute Head and Neck Cancer SPORE (P50 CA097190)
Cancer-AACR Innovative Research (SU2C-AACR-IRG-04-16)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: anti-PD-1 therapy, metformin, tumor hypoxia, tumor microenvironment, cancer immunotherapy resistance, combination therapy, oxidative metabolism, T cell function, B16 melanoma, MC38 colon carcinoma, antitumor immunity
MeSH terms: Tumor Hypoxia, Antineoplastic Agents, Immunological, Animals, Cytotoxicity, Immunologic, Drug Synergism, Energy Metabolism, Melanoma, Experimental, Metformin, Oxygen Consumption, T-Lymphocytes, Cytokines, Lymphocytes, Tumor-Infiltrating, Mice, Tumor Microenvironment, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks